(Q47652834)

English

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

scientific article published on 12 October 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer (English)

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

object named as

Anna Truini

4

0 references

Miguel F Sanmamed

object named as

Miguel F Sanmamed

15

0 references

Jackeline Agorreta

object named as

Jackeline Agorreta

17

0 references

Joseph Schlessinger

12

object named as

Joseph Schlessinger

1 reference

Europe PubMed Central

4 February 2018

Katerina Politi

26

object named as

Katerina Politi

1 reference

Europe PubMed Central

4 February 2018

Mary Ann Melnick

10

object named as

Mary Ann Melnick

1 reference

Europe PubMed Central

4 February 2018

Scott Gettinger

1

object named as

Scott Gettinger

1 reference

Europe PubMed Central

4 February 2018

25

object named as

Roy S Herbst

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Kurt A Schalper

24

object named as

Kurt Schalper

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Soldano Ferrone

20

object named as

Soldano Ferrone

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Ignacio Melero, MD-PhD

16

object named as

Ignacio Melero

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

7

object named as

Anna Wurtz

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

author name string

Jungmin Choi

2

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Katherine Hastings

3

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Ila Datar

5

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Ryan Sowell

6

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Weilai Dong

8

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Guoping Cai

9

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Victor Y Du

11

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Sarah B Goldberg

13

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Anne Chiang

14

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Luis M Montuenga

18

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Richard Lifton

19

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Paula Kavathas

21

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

David L Rimm

22

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Susan M Kaech

23

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

publication date

12 October 2017

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Cancer Discovery

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

7

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

12

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

1420-1435

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Mutational signatures associated with tobacco smoking in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Impact of pre-adapted HIV transmission.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Genetic evolution of T-cell resistance in the course of melanoma progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

HTSeq--a Python framework to work with high-throughput sequencing data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Acquired and intrinsic resistance in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Signatures of mutational processes in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

A tumour suppressor network relying on the polyamine-hypusine axis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Xenome--a tool for classifying reads from xenograft samples.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5718941

26 August 2018

Identifiers

10.1158/2159-8290.CD-17-0593

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

0 references

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/29025772

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47652834&oldid=2164182609"